Skip to content

Normal Science

Brain healing
GraphAuthors

A reading list for frontier science

Articles across AI, biotech, forecasting, and emerging tech.

Recommendation GraphExplore who recommends whom across the networkBrowse AuthorsProfiles, influences, and key works
Weekly Digest — Free
Join researchers, founders, and analysts · Unsubscribe anytime

Categories

AllAIForecastingBioTechSecurity / OSINTMetascienceFinanceAI SafetyEnergyManufacturingCryptoStartups

Time

Sort

Yesterday

STAT+: Updated health data privacy rule sets standards for sharing records with apps

Katie Palmer·STAT News·1d ago

On Monday, the Department of Health and Human Services issued a long-awaited update to the Health Insurance Portability and Accountability Act privacy rule. Originally proposed in January 2021, HHS’ Office for Civil Rights finalized several updates to the rule intended to make it easier to share health information — to coordinate patients’ care between health providers, but also to make it easier for patients to access and share their own data.  The HIPAA privacy rule update puts a particular fo...

STAT+: After death in gene therapy trial for a brain disease, progress is reported

Jason Mast·STAT News·1d ago

Researchers on Friday presented detailed investigations into a gene therapy death that sparked fear and uncertainty last year among scientists who felt they had been approaching powerful treatments for a long list of brain diseases. The researchers did not conclude precisely what led to the patient’s death but proposed experiments to screen future therapies. “What I want everyone to take home is: I think we’re starting to build a framework for testing this,” said Nicholas Flytzanis, chief resear...

This Week

New addiction society guidance on medetomidine’s brutal withdrawal

Theresa Gaffney·STAT News·4d ago

Clinicians first noticed medetomidine in the Philadelphia drug supply during the spring of 2024. There was a cluster of overdoses one weekend, leaving patients more sedated and with lower heart rates than normal after receiving the reversal medication naloxone.  It raised some red flags, but amid a constantly changing drug supply, not many. None of the patients died, and most went home from the hospital the same day. It wasn’t until autumn, when patients started coming in with excruciating withd...

STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say

Elaine Chen·STAT News·5d ago

Pharma companies that make GLP-1 drugs have increasingly promoted telehealth companies that prescribe the popular treatments. With a new deal announced this week, one of those relationships is expected to grow more complicated. Eli Lilly has been featuring a telehealth company called Counsel Health on a list of providers for patients seeking a GLP-1 prescription. On Tuesday, Counsel said it would be acquired by the smart ring maker Oura, allowing Counsel clinicians access to the data gathered th...

5 takeaways from STAT’s investigation of the sprawling ‘three-parent IVF’ industry

Megan Molteni·STAT News·5d ago

The investigation started with a tip from a British couple.  After trying to have a second child for several years, they had signed up with a U.S.-based company called International Fertility Group (IFG), paying tens of thousands of dollars for access abroad to an experimental fertility procedure illegal in the U.S. and tightly regulated in the U.K. The procedure, known as MRT — for mitochondrial replacement techniques — is sometimes called “three-parent IVF,” because it involves creating embryo...

BioByte 179: Epilepsy Epilogue

Jacob Luo·Decoding Bio·6d ago

Subscribe nowRealizing DREADDsCatch up quick:Chemogenetics offers a viable therapeutic strategy to insert receptors in the human brain and control neuronal activity with drugs.Three patients with drug-resistant epilepsy experienced a 92.6% reduction in seizure frequency after chemogenetic treatment.Why it matters: Small molecule therapeutics that target the brain act globally. With chemogenetics, specific brain regions can be treated, and only treated areas will respond to the designer drug. Mor...

STAT+: Scientists debut map of basal ganglia, a key brain region involved in an array of diseases

Jonathan Wosen·STAT News·6d ago

A massive scientific collaboration meant to unravel the mysteries of the human brain has produced the most detailed map yet of the basal ganglia, a region closely associated with a wide array of psychiatric and neurologic disorders. Researchers profiled more than 25 million cells, generating a deluge of data that allowed them to generate a “parts list” of what cells are present in the basal ganglia and how they’re arranged. In the process scientists discovered a new type of neuron that appears t...

American Cancer Society revises guidelines, urges routine PSA screening for prostate cancer

Annalisa Merelli·STAT News·6d ago

In a major change to screening guidelines, the American Cancer Society recommended on Thursday that American men between ages 50 and 69 at an average risk of prostate cancer should test their prostate-specific antigen (PSA) blood levels every two years.  The prior guidelines, released in 2010, left testing for average-risk men to their discretion, after assessing cancer risk with a physician. Read the rest…

Older

Does Employment Slow Cognitive Decline? Evidence from Labor Market Shocks

littlexsparkee·6mo ago264pts

Founded in 1920, the NBER is a private, non-profit, non-partisan organization dedicated to conducting economic research and to disseminating research findings among academics, public policy makers, and business professionals.

Group averages obscure how an individual's brain controls behavior: study

hhs·6mo ago106pts

Studying brain scan data from individuals — not group averages — reveals key brain-function differences in children who struggle with goal-oriented tasks, a Stanford Medicine study found.

Underwater robot tracks sperm whale conversations in real time

thedebuglife·6mo ago57pts

Researchers print structural colour with an inkjet printer

zeristor·6mo ago59pts

A nanoparticle ink that can print structural colour onto flat or 3D surfaces could be used to create anti-counterfeit images, smart windows and displays, and vibrant artworks

Aging may be a program, not a breakdown

elo2000·1mo ago26pts

By deciphering the molecular signatures of millions of mouse cells, Junyue Cao has found that aging is not haphazard wear and tear but rather a “remodeling of the cell society.”

Urban Birds Are Rising Earlier Because of Traffic Noise (2013)

thunderbong·6mo ago32pts

A male house sparrow. Photo by Edoddridge via Wikimedia Commons Most city dwellers have been woken up at some point by the chirping of birds outside their apartment window, but a new...

Forget LASIK: Safer, cheaper vision correction without lasers or surgery

bookmtn·5mo ago31pts

Researchers are developing a futuristic alternative to LASIK that reshapes the eye without lasers or incisions. Using mild electrical pulses and platinum contact lenses, they temporarily soften the cornea so it can be molded into a new shape. Early tests on rabbit eyes successfully corrected nearsightedness in about a minute while preserving the eye’s structure.

Men's average testosterone levels have halved in last 50 years

samizdis·4mo ago21pts

Exclusive: Researchers warn of ‘major crisis in male reproductive health’ partly driven by obesity and diabetes

Perturb-MARS: Reading mouse experiments through a human lens

crescit_eundo·6mo ago21pts

Multiplexed in-vivo perturbations, interpreted by a foundation model that has only ever seen human tumors.

A plastic once thought harmless may be fueling fatty liver disease

gradus_ad·1mo ago20pts

One of the world's most common plastics may pose a hidden threat to liver health. Texas A&M researchers discovered that polyethylene microplastics can contribute to fatty liver disease, with potentially worse effects when combined with an unhealthy diet. Even more surprising, this widely used plastic was previously considered relatively harmless.

Castration extends life span in mice

gmays·12d ago7pts

Artificial Intelligence used to design new viruses

CaRDiaK·3mo ago16pts

Scientists made 16 successful viruses that had their genetic code designed by artificial intelligence.

Scientists untangle the biology of an 'undruggable' cancer gene

gumby·1mo ago6pts

https://archive.ph/4uZAghttps://www.cell.com/molecular-cell/abstract/S1097-2765(26)0...

Decline in IQ linked to frequent or dependent use of cannabis use in youth

vixen99·4mo ago6pts

Intelligence quotient decline following frequent or dependent cannabis use in youth: a systematic review and meta-analysis of longitudinal studies - Volume 51 Issue 2

Fossilisation processes and our reading of animal antiquity

joebig·3mo ago8pts

Earth Tipped on Its Side During the Age of Dinosaurs–and Not Just Once

gumby·1mo ago6pts

When Earth tips over to restore its rotational balance, sea levels shift around the globe—episodes scientists have now traced to the age of dinosaurs.

Laser Phase Plate Cryo-Electron Microscopy

peteforde·5mo ago7pts

Learn how Biohub and UC Berkeley solved cryo-EM's contrast problem with a laser phase plate, opening a new window into the molecular machinery of living cells.

1 in 8 cancer cases are caused by infections

bookofjoe·1mo ago5pts

Four pathogens account for most infection-related cancers, a new study highlights, but the tools to prevent them range from well-established vaccines to treatments still under development.

Tell HN: An inside view of Montana's new biotech law

niklas_anzinger·2mo ago5pts

Montana passed a law called SB535. It builds on right-to-try (pre-approval access with informed consent, Phase 1 safety data etc.) but goes much further, fixing problems with those laws.Alex Tabarrok called it "the most important regulatory innovation in drug approval in my lifetime" (https://marginalrevolution.com/marginalrevolution/2026/06/mo...). Was posted here but died in /new (https://news.ycombinator.com/item?id=48559525). The mods suggested this post.I contributed ideas to the law and am now implementing it through my company. I invested in biotech for years and watched companies struggle. I built the biotech ecosystem in Prospera as an alternative, concluded it was too early, and now think Montana is the best place to prove this.Why this exists: When FDA approves a bad drug, heads roll. When it delays a good one, the deaths are statistical and nobody gets blamed ("invisible graveyard"). So the incentive is overcaution, which is why the cost per approved drug has roughly doubled every 9 years for decades ("Eroom's Law"). Founders are in the "Valley of Death" around Phase 1: grants are no longer available, and commercial money wants assurance the drug will pass the next trial. Only ~10% of post-Phase 1 drugs get approved, but 68% of failed trials don’t stop because they found lack of safety or efficacy but commercial reasons (Williams et al., PLOS ONE 2015). Federal Right to Try and Expanded Access haven't fixed this. Federal reform is super-hard.What Montana allows: A physician can give an experimental treatment outside a trial if: it completed FDA Phase 1 under an active IND; a state-registered private review board (ETRB) approved the protocol; it's delivered at a state-licensed clinic; consent exceeds the federal standard & adverse events need to be reported. The key is: sponsors and clinics can charge.Why this time it's different: The risk-reward ratio is what's broken. Right to Try and Expanded Access don't let sponsors charge, so treating a patient is risk plus expense. Montana is the first state law where sponsors of IND-stage drugs can price in that risk. Trial recruitment today is a price-control system: per-patient cost is around $50-100k, typically has a ceiling upward on what it can pay patients ("undue inducement") and a floor downward (no profit, only at cost in RTT / EA). Montana removes both (I know this will lead to lots of debate, let’s have it.)So this is not a free for all, the additional liberties come with tough oversight. An ETRB is Montana's version of an IRB: safety review, consent, mandatory outcome reporting, and you can't withhold safety information from patients. That’s the truth-funding mechanism.What companies can do now: If you have a Phase 1 asset stuck in the Valley of Death: treat patients, negotiate payment, get real-world data, use it to sharpen your Phase 2/3 design.Disclosure: my company formed the first ETRB. The model is review fees, like an IRB; no equity in applicants, no payment by outcome; COI policy and board bios public; decision letters published with applicant consent; annual outcome report required.Objections:- Someone gets hurt? Same as trials and ordinary care: US legal system, legal recourse.- FDA shuts it down? They haven't said they won't, but historically FDA goes after grey-market clinics, not state laws; we're asking for safe harbor, but some companies aren't waiting.- Snake oil? Bad actors want to fly under the radar, and Montana makes that hard.What's needed: Biotechs with Phase 1+ assets willing to move before full FDA assurance, to build the evidence that gets the agency on board - the point is not to skip FDA, but to reduce the cost of data. And ex-FDA reviewers, IND operators, IRB members telling us where this breaks.Happy to answer anything.

Nocturnal migratory birds follow rhythm of the moon

hhs·6mo ago5pts

All of Us study finds thousands of new genetic variants affecting drug responses

Anil Oza·STAT News·6d ago

A study of nearly 100,000 Americans identified thousands of new variants in a set of genes that influence our responses to prescription drugs, thanks to the inclusion of participants from a more diverse set of ancestries than previous studies of these so-called pharmacogenes. Using data from the National Institute of Health’s All of Us program, the researchers found that every participant carried at least one variant in the 16 pharmacogenes they studied, and that one in four participants had tak...

Decoding smell: Study reveals how odor signals shapeshift in the wind

hhs·3mo ago4pts

New research investigates the shifting patterns of odors as they travel through the air. The findings may help explain how animals navigate using smell and eventually inform development of odor-finding robots.

STAT+: BMI alternative would flip obesity diagnosis for millions, study finds

Andrew Joseph·STAT News·7d ago

LONDON — Millions of people would have their obesity diagnoses flipped — from having obesity to not, and vice versa — if an alternate way of defining the disease supplanted the standard body mass index measure, according to a new study that argues such an approach could lead to better care for patients.  The study, published Wednesday in the journal Nature, is the latest volley in a debate about the limitations of the body mass index, and what could possibly replace it. BMI is deeply entrenched ...

The U.S. may soon lose measles elimination status

Theresa Gaffney·STAT News·7d ago

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. We’re working today here at STAT. Send story ideas (I’m still on the addiction beat!), your favorite workday lunch, and good vibes: theresa.gaffney@statnews.com Read the rest…

STAT+: Pharma is a ‘mixed bag’ when providing drug access to low- and middle-income countries, analysis finds

Ed Silverman·STAT News·8d ago

Many large pharmaceutical companies are taking steps to improve access to their medicines in low- and middle-income countries, but progress has been mixed and more action is needed to ensure wide availability, a new analysis found. Notably, more drugmakers are planning to reach patients before a product launch — access plans now cover 69% of late-stage pipeline candidates compared with 18% in 2018. And across the pipeline, 95% of late-stage experimental drugs developed with a nonprofit partner h...

STAT+: Gene therapy’s long-debated cancer risk materializes

Meghana Keshavan and Brittany Trang·STAT News·9d ago

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The tumors possibly connected to pediatric gene therapies make me sad. Babies.  The need-to-know this morning Vir Biotechnology said monthly injections of two experimental medicines reduced hepatitis D virus to undetectable levels in 44% of patients compared to none of the patients who received delayed treatment with the same regimen. The result achieved the primary goal of...

Liver experts finally agree on what acute-on-chronic liver failure is

Isabella Cueto·STAT News·9d ago

Liver doctors from around the world have come to agree on a definition for a common and potentially fatal liver complication.  Acute-on-chronic liver failure is what happens when someone with underlying liver disease has their condition exacerbated by an acute injury. In the U.S., that often looks like long-simmering cirrhosis suddenly worsened by alcohol or a viral infection. Read the rest…

Survival after sudden cardiac arrest didn’t improve despite training bystanders, emergency responders

Elizabeth Cooney·STAT News·9d ago

CHICAGO — Sudden cardiac arrest statistics are chilling. In the United States, 350,000 people’s heartbeats, breathing, pulse, and blood circulation will all halt outside hospitals this year, seemingly out of the blue. These are not heart attacks. Only 1 in 10 people will survive them.  CPR and defibrillation can save their lives (and brains), but that depends on bystanders and emergency response systems being both nearby and prepared to step in — immediately. Survival chances drop by 10% for eve...

Lowering blood pressure after stroke or with diabetes poses challenges, in research and practice

Elizabeth Cooney·STAT News·10d ago

CHICAGO — High blood pressure has earned its reputation as the silent killer. If someone has diabetes or has had a stroke, the risk of serious cardiovascular events posed by hypertension climbs even higher.   Three studies presented Saturday at the American Heart Association’s scientific sessions reported on recent attempts to lower blood pressure in people with these challenging medical histories, and how medical care should reach across specialties to treat them. One small but diverse trial te...

‘Three-parent IVF’ was supposed to prevent mitochondrial disease. Studies are raising doubts

Megan Molteni and Edward Chen·STAT News·15d ago

The news out of the U.K. last year that eight healthy children had been born to mothers carrying disease-causing mutations in their mitochondria showed the promise of a pioneering reproductive technique known as “three-parent IVF.” The long-anticipated results seemingly showed the procedure, formally called mitochondrial replacement techniques, or MRT, could reduce the risk of babies inheriting sometimes fatal diseases, and raised hopes that other countries, such as the U.S. where MRT is banned,...

Are you pursuing MRT as a treatment for infertility? Tell us about your experience

STAT Staff·STAT News·16d ago

Over the last eight months, STAT has investigated the ways MRT is marketed as a fertility treatment for older women, despite scant evidence it works. The procedure, popularly called mitochondrial replacement techniques or “three-parent IVF,” is illegal in the United States, but it is accessible via a sprawling for-profit tourism industry, connecting women in the U.S. and Europe to clinics abroad.Read the rest…

Women travel thousands of miles for a reproductive moonshot. Scientists say they’ve been misled

Megan Molteni·STAT News·16d ago

TIRANA, Albania — As you drive from the Tirana International Airport toward the heart of the Albanian capital, car dealerships and shopping center-lined freeways give way to tidy rows of Communist-era housing blocks, their concrete walls splashed in Funfetti-hued dazzle camo — reminders of the country’s darker periods hiding beneath a cheerful riot of cheap paint. Continue south and on your right, freshly laid roads snake up into hills dotted with luxury homes behind high white walls and securit...

STAT+: HHS green lights six peptides, despite concerns from FDA scientists

Meghana Keshavan·STAT News·20d ago

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. I have a cold again. Cure it, science. HHS opens peptide floodgates, despite concerns from FDA scientists The Trump administration is giving the peptide craze a regulatory boost. HHS issued a policy allowing licensed pharmacies and physicians to temporarily compound six experimental peptides, including the popular injury-recovery duo BPC-157 and TB-500, without fear of fede...

STAT+: Vertex kidney disease drug scrutinized for infection risk

Adam Feuerstein·STAT News·20d ago

This is the online version of Adam’s Biotech Scorecard, a weekly newsletter featuring exclusive, spicy analysis on the biotech industry. Sign up here to get it delivered to your inbox. Spain is amazing. I was in Madrid for five days covering the ESMO conference. Now, I’m delivering this newsletter to you from a balcony overlooking the Mediterranean. Vertex kidney disease drug scrutinized for infection risk ahead of FDA approval decision So many medical meetings, so little time. While I was in Ma...

STAT+: New atlas of colorectal tumors sheds light on why cancers in young people are more dangerous

Angus Chen·STAT News·20d ago

For years, scientists have struggled to elucidate key biological differences between early onset colorectal cancer, typically in patients under the age of 50, and older patients. They’ve long believed that these cancers must be biologically distinct, since younger patients tend to be far more difficult to treat. They’re often diagnosed at later stages with tumors with more aggressive features. “Their survival, especially for the very youngest patients under the age of 35, may actually not be as ...

STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study

Elaine Chen·STAT News·21d ago

Eli Lilly on Wednesday said that its investigational drug was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study, further boosting the competitive profile of its medicine. In the head-to-head study, people on the highest dose of Lilly’s drug, called retatrutide, saw a 2.2 percentage-point reduction in a measure of blood sugar called A1c after 80 weeks, while those on Ozempic saw a 1.8 percentage-point reduction. Those on the highest do...

STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study

Elaine Chen·STAT News·21d ago

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got lots of news today to get into. Lilly’s triple-G drug beats Ozempic in head-to-head study Eli Lilly said this morning that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.Continue to STAT+ to read the full story…

STAT+: FDA offers new details on quicker approval pathway for personalized gene therapies

Margaret Manto·STAT News·22d ago

WASHINGTON – The Food and Drug Administration published draft guidance on Tuesday that would streamline approvals of some individualized gene therapies, a win for rare disease advocates who have criticized the agency’s approach to these treatments.  “It’s sort of putting a flag in the ground and saying, ‘This is important,’” Paul Scribner, vice president of community programs and education at the PKD Foundation, said of the draft guidance at a rare disease event on Tuesday.  Breakthroughs in gen...

STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down

Elaine Chen·STAT News·22d ago

Artiva Biotherapeutics said Tuesday that it’s winding down after two patients died in a trial testing its cell therapy for autoimmune diseases, the latest in a series of safety events that have emerged in a promising research field. One participant in the Phase 2 study died from a neurological complication after receiving the treatment, an NK cell therapy. Researchers determined the death was likely not related to the cell therapy itself, but to a chemotherapy that was given before the cell ther...

STAT+: Missouri AG warns Lilly to stop requiring data from hospitals seeking 340B drug discounts

Ed Silverman·STAT News·22d ago

Missouri Attorney General Catherine Hanaway (R) has warned Eli Lilly to discontinue its practice of requiring hospitals to provide claims data to receive discounted medicines under a federal program, a sign that more states are pushing back against such moves by drugmakers. In an Oct. 26 cease-and-desist letter sent to the company, Hanaway maintained that Lilly has “broken” its promise to sell its medicines under the 340B Drug Pricing Program to eligible hospitals in the state. As a result, she ...

STAT+: Pennsylvania Dutch country, tired of waiting for biopharma, builds drug company of its own

Jason Mast·STAT News·22d ago

LANCASTER, Pa. — They saved Petunia first. She was the second cow. Her brother Louie had died within hours of his birth. But over two harrowing, sleepless nights, the three researchers kept Petunia alive to wheel her from the barn to the veterinary hospital and inject her with a virus carrying new genes. Petunia had a bovine form of maple syrup urine disease (MSUD), a life-threatening condition that is also unusually prevalent within the Mennonite community here. The goal wasn’t to save the 79-p...

Vadim Gladyshev and the Science of Aging

Eric Topol·Eric Topol·22d ago

Vadim Gladyshev, PhD, Professor of Medicine at Brigham and Women's Hospital, Harvard Medical School, elected to the National Academy of Science, is a prolific science of aging researcher. We covered many topics including:Subscribe now—The nature of aging, and how it is different from biological aging (with glossary below)—The clocks of biological aging, which he considers biomarkersproteomic organ clock paper transcriptomic clock paper mAge (multimodal) clock with wearable preprint facial clock ...